Literature DB >> 18840814

Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs.

Louise R Howe, Scott M Lippman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18840814      PMCID： PMC2567416          DOI： 10.1093/jnci/djn347

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  63 in total

1.  Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.

Authors:  Kotha Subbaramaiah; Larry Norton; William Gerald; Andrew J Dannenberg
Journal:  J Biol Chem       Date:  2002-03-18       Impact factor: 5.157

2.  Nonsteroidal anti-inflammatory drug use and breast cancer risk.

Authors:  M Cotterchio; N Kreiger; M Sloan; A Steingart
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-11       Impact factor: 4.254

3.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.

Authors:  Ari Ristimäki; Anna Sivula; Johan Lundin; Mikael Lundin; Tiina Salminen; Caj Haglund; Heikki Joensuu; Jorma Isola
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

4.  Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis.

Authors:  Pia Wülfing; Raihanatou Diallo; Christine Müller; Christian Wülfing; Christopher Poremba; Achim Heinecke; Achim Rody; Robert R Greb; Werner Böcker; Ludwig Kiesel
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-15       Impact factor: 4.553

5.  Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis.

Authors:  Haruna Takeda; Masahiro Sonoshita; Hiroko Oshima; Ken-ichi Sugihara; Patricia C Chulada; Robert Langenbach; Masanobu Oshima; Makoto M Taketo
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

6.  Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer.

Authors:  Trista W Johnson; Kristin E Anderson; DeAnn Lazovich; Aaron R Folsom
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-12       Impact factor: 4.254

7.  Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.

Authors:  Louise R Howe; Kotha Subbaramaiah; Jay Patel; Jaime L Masferrer; Aparna Deora; Clifford Hudis; Howard T Thaler; William J Muller; Baoheng Du; Anthony M C Brown; Andrew J Dannenberg
Journal:  Cancer Res       Date:  2002-10-01       Impact factor: 12.701

8.  Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis.

Authors:  Howard F Tiano; Charles D Loftin; Jackie Akunda; Christopher A Lee; Judson Spalding; Alisha Sessoms; David B Dunson; Eleanor G Rogan; Scott G Morham; Robert C Smart; Robert Langenbach
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

Review 9.  Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer.

Authors:  Louise R Howe
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

10.  COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.

Authors:  G P Boland; I S Butt; R Prasad; W F Knox; N J Bundred
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640
View more
  5 in total

1.  COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin.

Authors:  Michelle D Holmes; Wendy Y Chen; Stuart J Schnitt; Laura Collins; Graham A Colditz; Susan E Hankinson; Rulla M Tamimi
Journal:  Breast Cancer Res Treat       Date:  2011-07-05       Impact factor: 4.872

2.  Regular aspirin use and breast cancer risk in US Black women.

Authors:  Jaclyn L F Bosco; Julie R Palmer; Deborah A Boggs; Elizabeth E Hatch; Lynn Rosenberg
Journal:  Cancer Causes Control       Date:  2011-08-30       Impact factor: 2.506

3.  Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study.

Authors:  Deirdre P Cronin-Fenton; Lars Pedersen; Timothy L Lash; Søren Friis; John A Baron; Henrik T Sørensen
Journal:  Breast Cancer Res       Date:  2010-03-01       Impact factor: 6.466

Review 4.  Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications.

Authors:  Antonio Macciò; Clelia Madeddu
Journal:  ScientificWorldJournal       Date:  2011-10-27

Review 5.  Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality.

Authors:  Michelle D Holmes; Wendy Y Chen
Journal:  Breast Cancer Res       Date:  2012-12-10       Impact factor: 6.466
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.